Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a pioneering developer of connected add-on devices for drug delivery devices, have officially announced a strategic partnership with the adaptive DOSE platform hardware add-on technology to develop and deploy digital companion apps.
According to certain reports, the stated collaboration will provide comprehensive connectivity and data capture solutions for dosing, storage, and injection techniques. The idea behind doing so is rooted in reshaping the whole management of injectable medications.
To understand the significance of such a development, we must take into account how injectable therapies actually play a critical role in the context of managing many chronic conditions. Despite their clear importance, though, they continue to pose significant challenges. These challenges include dosing regimens, fear of injections, and variability in injection technique, as they all can hinder adherence and compromise safety.
On top of that, improper storage can also impact medication efficacy, and in case that wasn’t enough, limited data capture makes it difficult to monitor patient progress effectively.
Fortunately enough, the collaboration will try and address these challenges by providing a comprehensive digital solution which, on its part, can seamlessly support patients and healthcare providers in optimizing injectable therapies.
More on that would reveal how the given development will bring forth an innovative digital companion system capable of integrating hardware and software. The stated system will also be designed to work alongside the Glooko platform, which is currently used by more than 8,200 diabetes clinics worldwide.
The latter link-up will basically facilitate the capture and analysis of critical information about injectable therapies from Innovation Zed’s DOSE platform technology, and therefore, offer enhanced support for healthcare providers and patients alike.
“Our partnership with Glooko represents a significant step forward in the integration of our smart drug delivery solutions with a leading digital health platform,” said Dr. Dean Minnock, Chief Executive Officer of Innovation Zed. “Together, we can offer unparalleled support to patients and healthcare providers, improving the management of injectable therapies worldwide.”
Talk about the incentive of using such digital companion apps on a slightly deeper level, we begin from its promise to improve adherence. This includes accurate recording and monitoring of dosing schedules to support adherence and optimize therapy outcomes.
Next up, we have the potential for enhanced safety, as the technology can offer guidance on proper storage conditions to maintain medication efficacy and educational resources on correct injection techniques.
Another benefit coming into here play here is of greater patient confidence. The stated confidence comes from how these apps can provide feedback on injection techniques to improve patient confidence and safety.
Rounding up highlights would be the prospect of streamlined data management. You see, the technology in question can tread up a long distance to facilitate real-time data capture and connectivity for a wide range of injectable medications, thus delivering valuable insights for healthcare professionals.
Founded in 2011, Glooko’s rise up the ranks is orchestrated by its bid to improve health outcomes of people with chronic conditions. This the company does through a specialized assortment of personalized, intelligent, connected care and life sciences platforms. Glooko’s excellence in what it does can also be understood once you consider its solutions are deployed in more than 30 countries, 10,000+ clinical locations, all while enjoying a connection with over 200 devices. In fact, with more than 4.4 million people worldwide who have used Glooko platforms, Glooko now boasts the largest installed base of patients living with diabetes.
“We are excited to partner with Innovation Zed to bring this cutting-edge digital companion system to market,” said Mike Alvarez, Chief Executive Officer of Glooko. “This collaboration will enable us to provide comprehensive support for patients and their healthcare providers, ultimately enhancing the treatment experience and improving outcomes. This partnership, combined with our ongoing platform development, reflects Glooko’s continued focus on increasing the benefits delivered to patients and clinics.”
